Back to top
more

Immunomedics, Inc. (IMMU)

(Delayed Data from NSDQ)

$14.17 USD

14.17
3,000,204

+0.18 (1.29%)

Updated Oct 11, 2019 03:58 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for IMMU

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Immunomedics, Inc. [IMMU]

Reports for Purchase

Showing records 1 - 20 ( 29 total )

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IMMU

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

09/17/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/12/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

09/11/2019

Company Report

Pages: 4

Competitor Antibody-Drug Conjugate Candidate Toxicity Profile Should Alleviate Concern, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

09/03/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/08/2019

Company Report

Pages: 5

Indication Profile Clarified; IMMU-132 Filing on Track; 2Q19 Financials Reported; Reiterate Buy; Lowering PT to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

07/23/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

06/04/2019

Company Report

Pages: 4

Standing Firm on Sacituzumab Lung Cancer Prospects; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/13/2019

Company Report

Pages: 5

Delayed Sacituzumab Market Entry Does Not Shake Our Confidence; Reiterate Buy and Lowering PT to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

04/30/2019

Company Report

Pages: 5

Recent Weakness Creates Favorable Entry Point Given Lucrative Asian Licensing Deal; Reiterate Buy; Raising Target to $29

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

04/24/2019

Company Report

Pages: 5

Balversa Urothelial Carcinoma Profile Bodes Well for Immunomedics; Our KOL Call Expert Opines Positively; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

04/02/2019

Company Report

Pages: 3

Our Forecasts Take Sacituzumab Competition Into Account; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/04/2019

Company Report

Pages: 34

Shifting the Paradigm in Breast Cancer, and Much More; Initiating at Buy and $28 Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 75.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/06/2018

Company Report

Pages: 8

Very busy second half - Q2 results and clinical trial progress

Provider: Edison Investment Research Limited

Price: .00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/14/2013

Company Report

Pages: 4

Dropping Coverage

Provider: Wedbush Securities Inc.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

09/10/2012

Industry Report

Pages: 44

September 2012 Potential Catalysts & Milestones - Monthly Update

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/27/2012

Company Report

Pages: 5

Downgrading to NEUTRAL

Provider: Wedbush Securities Inc.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/09/2012

Company Report

Pages: 6

FQ3:12 - Next Up, ASCO Kicks off Data-Filled June - Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

02/09/2012

Company Report

Pages: 6

Quarterly Update - 90Y-clivatuzumab With Low-Dose Gemcitabine May Enhance Market Position in Pancreatic Cancer

Provider: Wedbush Securities Inc.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Immunomedics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

01/18/2012

Daily Note

Pages: 5

ASCO-GI Data Preview: 90Y-Clivatuzumab Plus Gemcitabine Tolerability Data Anticipated

Provider: Wedbush Securities Inc.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party